2C-EF-FLY

2C-EF-FLY
Clinical data
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • 2-[4-(2-fluoroethyl)-2,3,6,7-tetrahydrofuro[2,3-f][1]benzofuran-8-yl]ethanamine
PubChem CID
Chemical and physical data
FormulaC14H18FNO2
Molar mass251.301 g·mol−1
3D model (JSmol)
  • C1COC2=C(C3=C(C(=C21)CCN)OCC3)CCF
  • InChI=1S/C14H18FNO2/c15-5-1-9-11-3-7-18-14(11)10(2-6-16)12-4-8-17-13(9)12/h1-8,16H2
  • Key:NUNWOBYVOQRPKC-UHFFFAOYSA-N

2C-EF-FLY is a psychedelic drug of the phenethylamine, 2C, and FLY families.[1][2][3] It is the FLY (benzodifuran) derivative of 2C-EF and is a fluorinated derivative of 2C-E-FLY.[1][2][3][4] The in-vitro metabolism of 2C-EF-FLY and its monoamine oxidase (MAO) interactions have been described.[2][3] 2C-EF-FLY produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[1] It showed around half the potency of 2C-B-FLY and 2C-E-FLY in this assay, but was slightly more potent than 2C-I-FLY.[1] 2C-EF-FLY was first described in the scientific literature by Lea Wagmann and colleagues in 2018 or 2019.[5][1][2][3] It has been described as a novel designer drug.[3]

See also

References

  1. ^ a b c d e Halberstadt AL, Chatha M, Stratford A, Grill M, Brandt SD (January 2019). "Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran ("FLY") and benzodifuran ("DragonFLY") analogs". Neuropharmacology. 144: 368–376. doi:10.1016/j.neuropharm.2018.10.037. PMC 6863604. PMID 30385253.
  2. ^ a b c d Wagmann L, Brandt SD, Stratford A, Maurer HH, Meyer MR (February 2019). "Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases" (PDF). Drug Testing and Analysis. 11 (2): 318–324. doi:10.1002/dta.2494. PMID 30188017.
  3. ^ a b c d e Wagmann L, Hempel N, Richter LH, Brandt SD, Stratford A, Meyer MR (October 2019). "Phenethylamine-derived new psychoactive substances 2C-E-FLY, 2C-EF-FLY, and 2C-T-7-FLY: Investigations on their metabolic fate including isoenzyme activities and their toxicological detectability in urine screenings". Drug Testing and Analysis. 11 (10): 1507–1521. doi:10.1002/dta.2675. PMID 31299701.
  4. ^ Arbouche N, Gheddar L, Ameline A, Raul JS, Kintz P (2026). "Metabolic profiling of 2C-EF in human liver microsomes: Identification of major metabolites and biotransformation pathways". Toxicologie Analytique et Clinique. 38 (1): 57–64. doi:10.1016/j.toxac.2025.08.005. Retrieved 12 March 2026.
  5. ^ Wagmann L (2018). Psychoactive substances as substrates or inhibitors of enzymes in drug metabolism and transport (Ph.D. thesis). Universität Des Saarlandes. doi:10.22028/D291-27544. Retrieved 12 March 2026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.